The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy

Journal of Rheumatology

Volumn 41, Issue 8, 2014, Pages 1607-1613

  Barnabe, Cheryl ^a,b   Homik, Joanne ^c   Barr, Susan G ^a   Martin, Liam ^a   Maksymowych, Walter P ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Predictors of response; Remission; Rheumatoid arthritis

Indexed keywords

TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFECT; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; ETHNICITY; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIMPLIFIED DISEASE ACTIVITY INDEX; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CANADA; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DISABILITY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADULT; AGED; ALBERTA; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84905493793     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131451     Document Type: Article

References (20)

1. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Semin Arthritis Rheum 1995;38:727-35.
2. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23:S93-9.
3. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Semin Arthritis Rheum 2011;63:573-86.
4. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57.
5. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806.
6. Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C. Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res 2010;62:1128-43.
7. Thiele K, Huscher D, Bischoff S, Spathling-Mestekemper S, Backhaus M, Aringer M, et al. Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. Ann Rheum Dis 2013;72:1194-9.
8. de Punder YM, Fransen J, Kievit W, Houtman PM, Visser H, van de Laar MA, et al. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology 2012;51:1610-7.
9. Kuriya B, Sun Y, Boire G, Haraoui B, Hitchon C, Pope JE, et al. Remission in early rheumatoid arthritis - a comparison of new ACR/EULAR remission criteria to established criteria. J Rheumatol 2012;39:1155-8.
10. Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML, et al. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis 2012;71:681-6.
11. Barr SG, Martin L, Chung C, Maksymowych WP. Mandatory pharmacosurveillance-a Canadian model for access to therapy and research. Clin Exp Rheumatol 2004;22:S39-43.
12. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005;23:S14-8.
13. Gonzalez-Gay MA, Gonzalez-Juanatey C. Rheumatoid arthritis: obesity impairs efficacy of anti-TNF therapy in patients with RA. Nat Rev Rheumatol 2012;8:641-2.
14. Barnabe C, Thanh NX, Ohinmaa A, Homik J, Barr SG, Martin L, et al. Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission. Ann Rheum Dis 2013;72:1664-8.
15. Svensson B, Andersson ML, Bala SV, Forslind K, Hafstrom I. Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria. BMJ Open 2013;3:e003554.
16. Jayakumar K, Norton S, Dixey J, James D, Gough A, Williams P, et al. Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. Rheumatology 2012;51:169-75.
17. Verschueren P, Esselens G, Westhovens R. Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. Scand J Rheumatol 2009;38:166-72.
18. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Semin Arthritis Rheum 2010;62:22-32.
19. Tom BD, Farewell VT. Intermittent observation of time-dependent explanatory variables: a multistate modelling approach. Stat Med 2011;30:3520-31.
20. Norton S, Sacker A, Dixey J, Done J, Williams P, Young A, et al. Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality. Rheumatology 2013;52:2016-24.